These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26529310)

  • 1. Premarket Regulation of Tissue Engineered Medical Products in China.
    Wang C; Wang A; Feng X; Ke L; Huang Y; Han Q; Sun X; Yang Z
    Tissue Eng Part A; 2015 Dec; 21(23-24):2806-11. PubMed ID: 26529310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Supervision, administration and standard research related to tissue engineered medical products].
    Xi TF; Chen L; Zhao P
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2003 Nov; 17(6):480-7. PubMed ID: 14663949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.
    Bt Hj Idrus R; Abas A; Ab Rahim F; Saim AB
    Tissue Eng Part A; 2015 Dec; 21(23-24):2812-6. PubMed ID: 26192075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation Policy on Cell- and Tissue-Based Therapy Products in Korea.
    Lim JO
    Tissue Eng Part A; 2015 Dec; 21(23-24):2791-6. PubMed ID: 25759938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation Policy for Cell and Tissue Therapies in Australia.
    Sturm M
    Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of Cell- and Tissue-Based Therapeutic Products in Singapore.
    Kellathur SN
    Tissue Eng Part A; 2015 Dec; 21(23-24):2802-5. PubMed ID: 26096855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Product development of probiotics as biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S128-32; discussion S144-51. PubMed ID: 18181718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States.
    Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS
    Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in natural health product research: The importance of standardization.
    Shan JJ; Rodgers K; Lai CT; Sutherland SK
    Proc West Pharmacol Soc; 2007; 50():24-30. PubMed ID: 18605225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of manufacture--principles and purposes.
    Luff PR
    Dev Biol Stand; 1992; 79():155-8. PubMed ID: 1286749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Problems in microbial safety of advanced therapy medicinal products. Squaring the circle].
    Montag-Lessing T; Störmer M; Schurig U; Brachert J; Bubenzer M; Sicker U; Beshir R; Spreitzer I; Löschner B; Bache C; Becker B; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):45-51. PubMed ID: 20012926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environmental assessment requirements for live biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S112-4; discussion S144-51. PubMed ID: 18181713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering human tissue and regulation: confronting biology and law to bridge the gaps.
    Longley D; Lawford P
    Med Law Int; 2001; 5(2):101-15. PubMed ID: 14696620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(226):68611-88. PubMed ID: 15562555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue engineered constructs: perspectives on clinical translation.
    Lu L; Arbit HM; Herrick JL; Segovis SG; Maran A; Yaszemski MJ
    Ann Biomed Eng; 2015 Mar; 43(3):796-804. PubMed ID: 25711151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The regulation of allogeneic human cells and tissue products as biomaterials.
    Yano K; Tsuyuki K; Watanabe N; Kasanuki H; Yamato M
    Biomaterials; 2013 Apr; 34(13):3165-73. PubMed ID: 23410682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical trials with advanced therapy medicinal products].
    Schüssler-Lenz M; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):68-74. PubMed ID: 20011994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.